Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Detection, Accurate Staging, and Biologic Characterization of HCC With Hybrid 68Ga-PSMA-Dual -Contrast PET/MRI and PET/CT
NCT04762888Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Feb 2021
- Primary completion
- Jun 2025
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gallium ga-68 gozetotide in hepatocellular carcinoma (HCC), sponsored by Mayo Clinic. Primary endpoints: Number of HCC Lesions With High PSMA Uptake on Baseline 68Ga-PSMA-11 PET, Semi-Quantitative 68Ga-PSMA-11 PET Standardized Uptake Value (SUV) Metrics in HCC Lesions With High PSMA Uptake and 1 more. Started Feb 2021; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04762888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762888.